Show simple item record

dc.contributor.authorPark, Joon Ohen_US
dc.contributor.authorRyoo, Baek-Yeolen_US
dc.contributor.authorYen, Chia-Juien_US
dc.contributor.authorKudo, Masatoshien_US
dc.contributor.authorYang, Lingen_US
dc.contributor.authorAbada, Paolo B.en_US
dc.contributor.authorCheng, Rebeccaen_US
dc.contributor.authorOrlando, Mauroen_US
dc.contributor.authorZhu, Andrew X.en_US
dc.contributor.authorOkusaka, Takujien_US
dc.date.accessioned2017-04-06T03:18:05Z
dc.date.issued2016en_US
dc.identifier.citationPark, Joon Oh, Baek-Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ling Yang, Paolo B. Abada, Rebecca Cheng, Mauro Orlando, Andrew X. Zhu, and Takuji Okusaka. 2016. “Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis.” Oncotarget 7 (46): 75482-75491. doi:10.18632/oncotarget.12780. http://dx.doi.org/10.18632/oncotarget.12780.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32071892
dc.description.abstractPurpose REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. Results: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634–1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months for placebo (HR, 0.895; 95% CI, 0.690–1.161; p = 0.4023) for non-East Asians. Median overall survival in patients with baseline alpha-fetoprotein ≥ 400 ng/mL was 7.8 months for ramucirumab and 4.2 months for placebo (HR, 0.749; 95% CI, 0.519–1.082; p = 0.1213) for East Asians (n = 139), and 8.2 months for ramucirumab and 4.5 months for placebo (HR, 0.579; 95% CI, 0.371–0.904; p = 0.0149) for non-East Asians (n = 111). The most common grade ≥ 3 treatment-emergent adverse events in East Asians and non-East Asians included hypertension and malignant neoplasm progression. Materials and methods A post-hoc analysis of East Asians (N = 252) and non-East Asians (N = 313) in the intent-to-treat population was performed. Conclusions: In East Asians and non-East Asians, ramucirumab did not significantly prolong overall survival. In patients with baseline alpha-fetoprotein ≥ 400 ng/mL, a potentially larger survival benefit was observed in both subgroups. Safety for East Asians was similar to non-East Asians.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.isversionofdoi:10.18632/oncotarget.12780en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342754/pdf/en
dash.licenseLAAen_US
dc.subjectAsiansen
dc.subjectalpha-fetoproteinen
dc.subjectclinical trialen
dc.subjectliver neoplasmsen
dc.subjectvascular endothelial growth factor receptor-2en
dc.titleSecond-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysisen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorZhu, Andrew X.en_US
dc.date.available2017-04-06T03:18:05Z
dc.identifier.doi10.18632/oncotarget.12780*
dash.contributor.affiliatedZhu, Andrew
dc.identifier.orcid0000-0003-4873-5033


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record